Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic review

Fig. 3

Overall survival (blue) and progression-free survival (red) of patients diagnosed with metastatic breast cancer receiving second-line treatment, according to the most effective treatment in each study. Results are displayed from the study with lower OS to the study with higher OS. Results from TH3RESA and BOLERO-3 are not displayed because OS results were not provided. GBG 26/BIG 03–05, German Breast Group 26/Breast International Group 03–05 study. OS overall survival, PFS progression-free survival

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us